GENERAL PRINCIPLES FOR TREATMENT OF EQUINE JOINT DISEASES

Similar documents
Lameness & Non- Surgical Therapies of the Equine Athlete

Current Therapy for Degenerative Joint Disease in the Horse: PART 2 Johan Marais. BVSc, MSc, Private Bag X, Onderstepoort, 0110.

Equine degenerative joint disease medical treatment and management

Please see accompanying Full Prescribing Information.


Osteoarthritis. Dr Anthony Feher. With special thanks to Dr. Tim Williams and Dr. Bhatia for allowing me to use some of their slides

Intra-articular treatment. Dr. med. vet. Julien P. Troillet Orthogen Veterinary GmbH

Equine Regenerative Medicine. Regenerative Medicine IRAP and PRP in the Equine Athlete. Stem Cells. Stem Cells. Veterinary Medical Devices

Joint Health Optimum Flex Plus, Hi- Victory, Yucca, Herbal Respond

Proceeding of the NAVC North American Veterinary Conference Jan. 8-12, 2005, Orlando, Florida

Dr. Chris Bell BSc, DVM, MVetSc, Dip ACVS* *Elders Equine Veterinary Service, Winnipeg, MB, Canada

Live On Screen: Knee Injections ABCs of Musculoskeletal Care. Knee aspiration. Objectives. I have no disclosures.

4 2 Osteoarthritis 1

From Arthroscopy to Gene Therapy 30 Years of Looking in Joints

USA Product Label LEGEND / LEGEND MULTI DOSE. (hyaluronate sodium) Injectable Solution LEGEND MULTI DOSE. (hyaluronate sodium) Injectable Solution

THERAPEUTICS USE IN EQUINE MUSCULOSKELETAL DISEASE

MANAGING THE OA-AFFLICTED DOG

State of the Science

TREATMENT STRATEGIES FOR EQUINE BACK DISEASES

Russell Parker BVSc MSc DipECVS MRCVS Liphook Equine Hospital LIPHOOK EQUINE HOSPITAL

Thoracic Limb Lameness. Jason Eisele, DVM, CCRP, DACVS

Rheumatoid arthritis

Ricardo E. Colberg, MD, RMSK. PM&R Sports Medicine Physician Andrews Sports Medicine and Orthopedic Center American Sports Medicine Institute

FOR OSTEOARTHRITIS Brian Trumpatori, DVM, DACVS

Non-Operative Options for Articular Cartilage Issues in the Athlete s Knee

Tendon & Ligament Injuries

NOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg.

Proceedings of the 36th World Small Animal Veterinary Congress WSAVA

Osteoarthritis What is new? Dr Peter Cheung, Rheumatologist, NUHS

Proceedings of the Annual Resort Symposium of the American Association of Equine Practitioners AAEP

Aching Equine Joints: A PAIN FOR BOTH HORSES & OWNERS

Common Lameness in Dressage Horses, Risk Factors and Treatment Options

Osteoarthritis. RA Hughes

Review of the Scientific Basis for Use of Intra- Articular Corticosteroids in the Horse

STRIDE PLUS STRIDE PLUS. Nutritional Maintenance of Healthy Cartilage and Joints in Dogs. 100%

AIMS We will all come across osteo- and rheumatoid arthritis whatever our clinical practice Overview of pathology of osteoarthritis, its assessment an

Arthritis of the Knee

ORTHOPEDICS BONE Recalcitrant nonunions In total hip replacement total knee surgery increased callus volume

Proceedings of the 11th Annual Resort Symposium of the American Association of Equine Practitioners AAEP

Dukes Vet Practice

Joint Injection Challenge The art of good injection therapy is to place the appropriate amount of the appropriate medication into the exact site of th

An Owner's Guide to Natural Healing. Autologous Conditioned Plasma (ACP)

Wanlamkupar Khongwir, Subhasish Saha and Tashi Khonglah

160 Belmore Rd, Randwick

Foot, Ankle, Knee & Hip Surgery Update. What s s New. Platelet Rich Plasma (PRP) Platelet Rich Plasma Total Ankle Replacement.

Osteoporosis. World Health Organisation

Prevention Diagnosis Assessment Prescription and /or application of wide range of interventions and PRM program management

Evaluation and Treatment of Knee Arthritis Classification of Knee Arthritis Osteoarthritis Osteoarthritis Osteoarthritis of Knee

Ankle Arthritis and Ankle Replacement

Clinical Evidence Report

Arthritis of the Knee

Musculoskeletal corticosteroid use:

A GUIDE FOR PATIENTS KNEE PAIN RELIEF THAT JUST CAN T WAIT

Arthritis. What is arthritis? Who is affected? What treatment options are available?

Managing Equine Joint Disease

Arthrex ACP Double Syringe. ACP - Autologous Conditioned Plasma

Magnetic Resonance Imaging of Equine Tarsal Disorders

Joint Injections Why are joint injections performed? Does joint arthritis benefit from injections?

TEMPLATE FOR RELEVANT LABEL PARTICULARS (RLPs) (Veterinary Produc~ts) Select appropriate:

Navicular Bursa (fluid sack at back of bone) Pedal (coffin) bone Navicular bone

EFFECTS OF ORAL AND INTRAMUSCULAR USE OF CHONDROITIN SULFATE IN INDUCED EQUINE ASEPTIC ARTHRITIS.

EQUINE OSTEOARTHRITIS: MANAGEMENT OVER VIE W, OPTIONS AND TREATMENTS

In the Treatment of Patients With Knee Joint Osteoarthritis, Are Platelet Rich Plasma Injections More Effective Than Hyaluronic Acid Injections?

Preliminary Report Choosing Wisely Identifying Musculoskeletal Interventions with Limited Levels of Efficacy in the Shoulder & Elbow.

UPDATES ON MANAGEMENT OF OSTEOARTHRITIS

Intent to Consider the Appropriate Classification of Hyaluronic Acid Intra-articular Products

MANAGING CANINE OSTEOARTHRITIS

Treatment and Rehabilit Treatment and ation Plans for Various Musculoske Musculosk letal Conditions

Is Viscosupplementation Effective in Reducing Osteoarthritis Knee Pain?

ESWT Mechanisms of Action in Veterinary Applications

2/28/08. Member has documented symptomatic osteoarthritis of the knee substantiated by x-ray defined as:

What does the application of a deep-penetrating therapeutic laser actually accomplish?

High Impact Rheumatology

THAT S PROVEN FOR THE LONG RUN

The Rheumatoid Hand Deformities & Management. Dr. Anirudh Sharma Resident Department of Orthopedics

Zahra Jahangard Clinical pharmacy Resident

Ankle Arthroscopy.

A Disease Modifying Osteoarthritis Drug

Medications for Degenerative Arthritis

Are you looking for powerful and long-lasting pain relief from knee osteoarthritis?

International Journal of Orthopaedics Sciences 2018; 4(1): Varun GBS, Vignesh Kumar V, Raj Lavadi and Muralidhar N

INTRA-ARTICULAR HYALURONAN INJECTIONS

Index. Note: Page numbers of article titles are in boldface type. Hand Clin 21 (2005)

Priorities Forum Statement GUIDANCE

Cartilage Care in the Mature Female Athlete

SMF PCP Treatment & Referral Guideline Orthopedics Developed February 1, 2003 Revised: October, 2011

HORSE LOCOMOTION: why and how to supplement?

Ankle Replacement Surgery

Performance Lameness in Reining Horses


Inflammation is Not the Enemy

Salicylates: Interactions 10/14/2009. Salicylates DRUGS USED IN THE MANAGEMENT OF MUSCULOSKELETAL DISORDERS. Chapters 17, 18, 34 & Pages 577 &

Nursing Management: Musculoskeletal Trauma and Orthopedic Surgery. By: Aun Lauriz E. Macuja SAC_SN4

REVIEW I-Flex and Management of Inflammation in Osteoarthritis

Osteochondritis Dissecans

Anabolic Therapy With Teriparatide Indications Beyond Osteoporosis

Rotator Cuff Tears. Dr. Anthony Levenda September, 2017

Arthritis. What is arthritis?

o Total knee arthroplasty is projected to grow 85% o Other studies predict up to 3.48 million TKA o 17% adults over age 45 have symptomatic OA

Navicular Syndrome/Heel Pain

Transcription:

GENERAL PRINCIPLES FOR TREATMENT OF EQUINE JOINT DISEASES Martin Waselau, Dr.med.vet, MS Diplomate ACVS, Diplomate ECVS - University of Helsinki - Eläinlääketieteellinen tiedekunta / Faculty of Veterinary Medicine

OUTLINE Clinical presentation of joint disease Pathophysiology General goals of treatment Expectations Conservative treatment Controlled exercise programs Systemic and local medications Shock wave; orthobiologics etc. Surgical treatment 2

CLINICAL PRESENTATION OF JOINT DISEASE Typically: Joint effusion Pain on palpation and/or manipulation Lameness But also: Exercise intolerance Poor performance IMPORTANT: Detailed history Clinical and lameness examination Radiographs, ultrasonography etc.... 3

CLINICAL PRESENTATION OF JOINT DISEASE 4

PATHOPHYSIOLOGY Traumatic joint diseases Trauma & inflammation Enzymatic cartilage degradation... 5

PATHOPHYSIOLOGY Traumatic joint diseases Enzymatic cartilage degradation Articular cartilage degeneration will result in DJD 6

PATHOPHYSIOLOGY Degenerative joint diseases 7

GENERAL TREATMENT GOALS AND OPTIONS Treated joints Osteoarthritic joints mainly treated +/- Healthy joints Two main goals: Relief pain and inflammation Stop progression of the disease Maintain joint health Options: Conservative/Medical management (Generalized OA) Surgical intervention (Full-thickness cartilage damage) 8

CONSERVATIVE THERAPY 9

I. SYSTEMIC TREATMENTS NSAIDs Mechanism of action: 10

I. SYSTEMIC TREATMENTS NSAIDs Indications: Typically used for acute injuries (reduce inflammation) Management of chronic OA (pain relief) Drugs and dosages: COX-1/2 inhibitors +/- selective COX-2 inhibitors 11

I. SYSTEMIC TREATMENTS NSAIDs Adverse effects: Gastrointestinal, renal and hematological Long-term use Rule out underlying disease Ensure appropriate water and food consumption 12

I. SYSTEMIC TREATMENTS Hyaluronic acid Hyaluronic acid = HA Normal component of joint fluid and articular cartilage Mechanism of action = not 100% known Anti-inflammatory - Granulocytes and macrophages - Inhibition of chemotaxis and phagocytosis - Lymphocytes - Reduction in stimulation, proliferation and migration - Free radical scavanger - Decreases formation and release of prostaglandins Stimulation of HA synthesis... 13

I. SYSTEMIC TREATMENTS Hyaluronic acid Indications: Acute synovitis Maintain general health; supportive therapy Treatment of multiple lesions (tendon sheaths/joints) Adjunct therapy Drugs and dosages: i.v. application of Hyonate 40mg/horse every 2 weeks (2-3x) Adverse effects: Not observed after i.v. administration 14

I. SYSTEMIC TREATMENTS PSGAG PSGAG: = Polysulfated glucosaminoglycane From bovine lung and trachea Contains mainly chondroitin sulfate Mechanism of action = not 100% known: HA synthesis Anti-inflammatory - Inhibition of interleukines, matrix metalloproteinases, prostaglandins etc. - Effect on synthesis and degradation of proteoglycane 15

I. SYSTEMIC TREATMENTS PSGAG Indications: Maintain general health; supportive therapy Treat multiple lesions joints Adjunct therapy Drugs and dosages: Adequan 500mg i.m. every 3-5 days for at least 5 treatments Practical: - 1 st month = 1 injection/week - 2 nd month =1 injection/2 weeks - 3 rd months = 1injection/month 16

I. SYSTEMIC TREATMENTS Glucosamin/chondroitin Mechanism of action: Provide components for cartilage synthesis Building bocks Poor scientific evidence Indications: See PSGAG Drugs and dosages: Several available products; oral application Poor bioavailability 17

I. SYSTEMIC TREATMENTS Future therapies Pentosan sulphate Multiple joint involvement 3mg/kg i.m. nce weekly for 4 weeks Bisphosphonates E.g. Tildren for NB-syndrome and bone spavin Adapted from human medicine osteoporosis therapy Reduces osteoclastic action Single injections or infusion Tetracyclines Anti-inflammatory effect 18

II. LOCAL TREATMENTS Corticosteroids Mechanism of action: 19

II. LOCAL TREATMENTS Corticosteroids Mechanism of action: Potent anti-inlammatory = pain relief Being used since 1950 s Indications: Mainly for management of clinically confirmed joint changes - OA - Not acute traumatic joint diseases Contraindication: Infectious arthritis 20

II. LOCAL TREATMENTS Corticosteroids Drugs: Betamethasone = Celestone Triamcinolone = Vetalog - Chondroprotective? - High-motion joints Methyl prednisolone = Depo Medrol - Potentially chondrodestructive - Low motion joints - Long-acting Combinations: Frequently with hyaluronic acid 21

II. LOCAL TREATMENTS Corticosteroids Dosages: Aftercare 1-3 days stall rest 22

II. LOCAL TREATMENTS Corticosteroids Adverse effects: Mainly local and not systemically Cartilage damage - Prevents anabolism - Potentially not true for inflammed or abnormal joints... Laminitis (0.5%) - Excessive dosages not 100% clear - Ponies - General guidlines - > 18mg triamcinolone?? - > 200mg methyl prednisolon?? - > 30mg betamethasone?? 23

II. LOCAL TREATMENTS Hyaluronic acid Mechanism of action: Refer to systemic therapy Viscosupplementation Indications: Refer to systemic therapy Adjunctive, rarely single use 24

II. LOCAL TREATMENTS Hyaluronic acid Drugs: Large variety of products available molecular weight differs General rule - The higher molecular weight, the better effect - < 500kDa = little effect Could, but should not be used as single intraarticular therapy - Excessive synovitis and pain joint flare... - Better: in combination with corticosteroids - Simultaneously anti-inflammatory 25

II. LOCAL TREATMENTS Hyaluronic acid Dosages: Mostly - Single injection and re-evaluate lameness Most benefit - 20mg/ once weekly for 3 weeks, but 26

II. LOCAL TREATMENTS Orthobiologics IRAP: Mechanism: Interleukin-1 receptor antagonist Blocks inflammatory receptor and thus, inflammation Produced from patients own blood 27

II. LOCAL TREATMENTS Orthobiologics 28

II. LOCAL TREATMENTS Orthobiologics IRAP: Indication - Early stages of joint disease - High motion joints Application - 2 3 treatments (1-8ml) 8-14 days apart - Left overs can be frozen @ -18 C for later use 29

30

II. LOCAL TREATMENTS Orthobiologics PRP: Platelet rich plasma Degranualation of platelets = release of growth factors Growth factors support healing / anti-inflammatory? No clear evidence in equine Adapted from human medicine 31

32

II. LOCAL TREATMENTS Shock wave Mechanism of action: Mainly unknown anecdotal reports... Analgesia Reduction in synovial protein levels... 33

SURGICAL THERAPY 34

SURGICAL TREATMENT Diagnostic arthroscopy Gold standard direct evaluation of joint health Benefit of lavage inflammatory mediators flushed out Surgical arthroscopy Removal of osteochondral fragments Reconstruction of articular fractures Synovectomy Joint resurfacing Articular grafting 35

SURGICAL TREATMENT 36

SURGICAL TREATMENT Arthrodesis Fusion of joint = salvage procedure 37

REFERENCES Textbooks Further study material Upon request 38

Q U E S T I O N S? 39